Evidence map›Paper›PMID 36733461›Full record

ArticleFrontiers in cell and developmental biology2023

Targeting Kaposi's sarcoma associated herpesvirus encoded protease (ORF17) by a lysophosphatidic acid molecule for treating KSHV associated diseases.

Misbahuddin M Rafeeq, Alaa Hamed Habib, Alaa F Nahhas, Najat Binothman, Majidah Aljadani, Jawaher Almulhim, Ziaullah M Sain, Mohammad Zubair Alam, Norah A Alturki, Qamre Alam and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Misbahuddin M RafeeqDepartment of Pharmacology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, KSA.
Alaa Hamed HabibDepartment of Physiology, Faculty of Medicine, King Abdulaziz University, Jeddah, KSA.
Alaa F NahhasBiochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah, KSA.
Najat BinothmanDepartment of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia.
Majidah AljadaniDepartment of Chemistry, College of Sciences and Arts, King Abdulaziz University, Rabigh, Saudi Arabia.
Jawaher AlmulhimDepartment of Biological Sciences, King Faisal University, Alahsa, KSA.
Ziaullah M SainDepartment of Microbiology, Faculty of Medicine, Rabigh, King Abdulaziz University, Jeddah, KSA.
Mohammad Zubair AlamPre-Clinical Research Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
Norah A AlturkiClinical Laboratory Science Department, College of Applied Medical Science, King Saud University, Riyadh, Saudi Arabia.
Qamre AlamMedical Genomics Research Department, King Abdullah International Medical Research Center, King Saud Bin Abdulaziz University for Health Science, Riyadh, Saudi Arabia.
Manish ManishSchool of Computer and Integrative Sciences, Jawaharlal Nehru University, New Delhi, India.
Rajnish Kumar SinghMolecular Biology Unit, Institute of Medical Sciences, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
King Abdulaziz University · SABanaras Hindu University · INJawaharlal Nehru University · INKing Abdullah International Medical Research Center · SAKing Faisal University · SAKing Saud University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kaposi's sarcoma associated herpesvirus (KSHV) is causative agent of Kaposi's sarcoma, Multicentric Castleman Disease and Pleural effusion lymphoma. KSHV-encoded ORF17 encodes a protease which cleaves -Ala-Ala-, -Ala-Ser- or -Ala-Thr-bonds. The protease plays an important role in assembly and maturation of new infective virions. In the present study, we investigated expression pattern of KSHV-encoded protease during physiologically allowed as well as chemically induced reactivation condition. The results showed a direct and proportionate relationship between ORF17 expression with reactivation time. We employed virtual screening on a large database of natural products to identify an inhibitor of ORF17 for its plausible targeting and restricting Kaposi's sarcoma associated herpesvirus assembly/maturation. A library of 307,814 compounds of biological origin (A total 481,799 structures) has been used as a screen library. 1-oleoyl-2-hydroxy-sn-glycero-3-phospho-(1'-myo-inositol) was highly effective against ORF17 in

Indexed as

KSHVmalignanciesORF17proteasereactivation

Identifiers

PMID36733461
PMCPMC9888664
OpenAlexW4316669212

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.